Screening for PAH in Systemic Sclerosis: Does It Matter?

Author: Kevin Deane, MD
Date Published: February-2012
Source: Medscape Today

Pulmonary arterial hypertension (PAH) is a leading cause of mortality in patients with systemic sclerosis (SSc).[1] Once commonly thought to be a late complication of SSc, support for PAH as an early manifestation of disease is growing. PAH is present within 5 years of the onset of the first non-Raynaud symptoms of SSc in approximately 50% of patients.


AddThis Social Bookmark Button